Enclomiphene UPDATE

Enclomiphene

SARMs (unlike other androgenic compounds) have been designed to have tissue specificity, activating androgen receptors primarily in muscle tissue.

However there is an inherent risk of selectivity being reduced, particularly when dosages and research use time increases beyond those cited in studies.

In such cases there can be non selective effects such as a negative impact on the HPTA Axis.

PCT protocols are therefore an option to impart a reversal and mitigate this through a positive feedback on the HPTA axis

Positive Feedback

Traditionally SERMs can illicit a positive feedback loop on the HPTA through activation of the Estrogen Receptor, however the majority of these are POM compounds.

Clomiphene (Clomid) is one of these SERMs

Zuclomiphene is the (Z)-enantiomer and is more estrogenic as it is antigonadotropic due to activation of the Estrogen receptor (hence why Clomid can also give feminizing effects especially on the mental/emotional side due to ER activation)

Enclomiphene is the (E)-enantiomer and is gonadotropic due to blocking of the Estrogen receptor, hence this gives the positive feedback loop on the HPTA to stimulate the hypothalamus to synthesize and release gonadotropin-releasing hormone.

As Clomid is 62% Enclomiphene and it is typically dosed at 50mg, an equivalent dose of 25mg per day of Enclomiphene for 4 weeks post androgenic research equates to an adequate dosing level.

Purchase Here:

Quick View

Enclomiphene

30ml @ 12.5mg/ml  |  (30 x 12.5mg)

M.Wt: 598.089 g/mol Formula: C₃₂H₃₆ClNO₈ Solubility: Polyglycols, DMSO Purity: >98% Storage: at 20℃ 3 years Half life: - CAS No.: 7599-79-3

was last modified: January 29th, 2025

£39.99 Add to cart